These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30449328)

  • 21. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study of memantine in the treatment of major depression.
    Zarate CA; Singh JB; Quiroz JA; De Jesus G; Denicoff KK; Luckenbaugh DA; Manji HK; Charney DS
    Am J Psychiatry; 2006 Jan; 163(1):153-5. PubMed ID: 16390905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.
    Boada R; Hutaff-Lee C; Schrader A; Weitzenkamp D; Benke TA; Goldson EJ; Costa AC
    Transl Psychiatry; 2012 Jul; 2(7):e141. PubMed ID: 22806212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
    Cheon Y; Park J; Joe KH; Kim DJ
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.
    Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Grigg J; Tan R; Cheng J; Arnold A; Gurvich C
    CNS Drugs; 2018 Feb; 32(2):179-187. PubMed ID: 29549516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study.
    Pelton GH; Harper OL; Roose SP; Marder K; D'Antonio K; Devanand DP
    Int J Geriatr Psychiatry; 2016 Jun; 31(6):648-55. PubMed ID: 26559790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Veerman SR; Schulte PF; Smith JD; de Haan L
    Psychol Med; 2016 Jul; 46(9):1909-21. PubMed ID: 27048954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
    Mehta LR; McDermott MP; Goodman AD; Schwid SR
    Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
    Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
    Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy.
    Lancman ME; Fertig EJ; Trobliger RW; Perrine K; Myers L; Iyengar SS; Malik M
    Epilepsy Behav; 2016 Aug; 61():27-33. PubMed ID: 27315132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.
    Nakamura Y; Kitamura S; Homma A; Shiosakai K; Matsui D
    Expert Opin Pharmacother; 2014 May; 15(7):913-25. PubMed ID: 24673497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers.
    Das RK; Hindocha C; Freeman TP; Lazzarino AI; Curran HV; Kamboj SK
    Psychopharmacology (Berl); 2015 Sep; 232(18):3363-74. PubMed ID: 26093656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain.
    Wiech K; Kiefer RT; Töpfner S; Preissl H; Braun C; Unertl K; Flor H; Birbaumer N
    Anesth Analg; 2004 Feb; 98(2):408-413. PubMed ID: 14742379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.